Enterprise Value
5.868B
Cash
710.6M
Avg Qtr Burn
-109.2M
Short % of Float
8.51%
Insider Ownership
0.89%
Institutional Own.
-
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AYVAKIT (avapritinib) Details PDGFRA mutant GIST (Gastrointestinal Stromal Tumors) | Approved Quarterly sales | |
GAVRETO (parlsetinib) Details RET+ NSCLC (Non-small cell lung cancer), RET+ Thyroid cancer, solid tumors | Approved Quarterly sales | |
AYVAKIT® (avapritinib) Details Systemic Mastocytosis | Approved Quarterly sales | |
BLU-222 (CDK12) Details Cancer, Breast cancer | Phase 1/2 Data readout | |
BLU-451 Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 1/2 Update | |
BLU-945 +/- osimertinib Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 1/2 Update | |
Elenestinib Details Systemic Mastocytosis | Phase 1 Data readout |